Donaldson Company, Inc. announced on February 21 that it acquired Durham, North Carolina-based Isolere Bio, Inc.
With the addition of Isolere to Donaldson’s portfolio, Donaldson is positioned to create premier separation and filtration solutions for emerging genetic-based drugs. The financial terms of the acquisition were not disclosed.
Isolere Bio is an early-stage biotechnology company that develops novel and proprietary IsoTag reagents and accompanying filtration processes used for the purification and streamlined manufacturing of biopharmaceuticals. It was founded in 2017 by Kelli Luginbuhl, Ph.D, Professor Ashutosh Chilkoti and Joe McMahon.
Founded in 1915, Donaldson Company is a provider of filtration products and solutions used in various industry sectors, including commercial/industrial, aerospace, chemical, alternative energy and pharmaceuticals. The company has more than 140 locations on six continents. Donaldson’s revenue for the 12 months ending October 31, 2022, was $3.393B, a 13.93% increase year-over-year.
According to data captured in the LevinPro HC database, this acquisition represents the 26th Biotechnology transaction of 2023. The Biotechnology deal with the largest price tag in 2023, so far, is Sun Pharmaceutical Industries Limited purchase of Concert Pharmaceuticals, Inc. for $576 million.
